Intech Investment Management LLC Has $706,000 Stake in InMode Ltd. (NASDAQ:INMD)

Intech Investment Management LLC boosted its position in shares of InMode Ltd. (NASDAQ:INMD) by 36.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,300 shares of the healthcare company’s stock after purchasing an additional 11,260 shares during the period. Intech Investment Management LLC’s holdings in InMode were worth $706,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. River Road Asset Management LLC acquired a new position in shares of InMode during the fourth quarter worth about $8,572,000. Seizert Capital Partners LLC boosted its position in InMode by 105.2% during the 4th quarter. Seizert Capital Partners LLC now owns 250,627 shares of the healthcare company’s stock worth $4,185,000 after acquiring an additional 128,483 shares during the last quarter. Systematic Financial Management LP grew its stake in shares of InMode by 13.3% during the 3rd quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock worth $16,647,000 after acquiring an additional 115,492 shares in the last quarter. Barclays PLC raised its holdings in shares of InMode by 113.5% in the third quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock valued at $2,876,000 after purchasing an additional 90,173 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC lifted its position in shares of InMode by 12.9% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 720,750 shares of the healthcare company’s stock worth $12,217,000 after purchasing an additional 82,100 shares in the last quarter. Institutional investors and hedge funds own 68.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on INMD shares. Barclays raised their target price on shares of InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 5th. Needham & Company LLC restated a “hold” rating on shares of InMode in a report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, InMode currently has a consensus rating of “Hold” and a consensus target price of $22.25.

InMode Trading Up 1.1 %

Shares of INMD opened at $18.63 on Monday. The company’s fifty day simple moving average is $18.12 and its 200 day simple moving average is $17.70. InMode Ltd. has a 1-year low of $14.87 and a 1-year high of $21.92. The company has a market cap of $1.30 billion, a price-to-earnings ratio of 7.93 and a beta of 2.08.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.